HEAL ▶▶▶TH
How to improve PRRS control in 10 steps
It’s time for deep and thorough review of existing management strategies for PRRS, according to leading US expert Dr Neil DeBuse. Management strategies for PRRS must be closely examined based on new information from Denmark and the US on the recombination of viral isolates in the field.
BY TREENA HEIN, CORRESPONDENT
Dr Neil DeBuse, Minnesota Swine Repro- duction Center.
With regard to current and future control of Porcine Repro- ductive and Respiratory Syndrome (PRRS), experts such as veterinarian Dr Neil DeBuse at the Minnesota Swine Repro- duction Center believe a major change in strategy is warrant- ed. That is, that the use of modified live virus (MLV) vaccines should not be the industry’s primary or only tool for PRRS control. MLV vaccines contain living, weakened strains of a pathogen, which in theory do not cause disease. However, shedding of the strain from the MLV may occur for a period of 60–90 days following vaccination. It’s been known for 20 years, says Dr DeBuse, that PRRSv can undergo recombination events (where in the process of replication of two virus strains, a new one is produced by errors or by the event occurring in the same cells and host). In 2019, Danish vets documented the emergence of a novel PRRSv recombinant traceable directly to two parent MLV vaccine strains.
Recombination is common Dr DeBuse believes this sort of recombination event is quite common. “It is my belief that what hap- pened in Denmark is hap- pening every single week in the US,” says Dr DeBuse. “It’s because of Denmark’s relatively high national herd health status (about 80% negative or naïve herds there) and the high
16
degree of coordination between professional veterinarians that the recombination event was detected. I think this case points us towards an uncomfortable truth on a global level. That truth is because MLV vaccines represent an important source of new PRRSv strain emergence over time. The indus- try needs to carefully re-examine knowledge in this area.” Following the 2019 recombination event in Denmark, a com- mittee of the European Medicines Agency (EMA) reviewed the available data and released its conclusions in April 2021. In short, the benefits of MLV PRRS vaccines continue to out- weigh the risks, but additional warnings should be issued in order to continue ensuring the safe use of these vaccines, “in order to limit the opportunity for [them] to circulate and to reduce the risk and the frequency of recombination between PRRS viruses including PRRS vaccine strains”.
Breakthrough in PRRS Dr DeBuse says, “I believe our biggest breakthrough in PRRS will come from technologies that enable primary inter- vention strategies to avoid ‘dual infection’ of sows, piglets yet to be born and piglets still nursing their mothers. As veterin arians, we need to have the discipline to implement new solutions that adhere to that principle – avoiding dual infection.” Technology exists, according to DeBuse, in established prod- ucts that could be helpful to avoid the overuse of MLV vac- cines in concurrently infected populations. Examples include pharmaceutical products like tilmicosin (Pulmotil, Elanco), which has demonstrated ability to reduce PRRS in the field. Dr DeBuse says that both MJ PRRS vaccines (Phibro) and a novel intranasal vaccine from Aptimmune have clear bene- fits immediately upon occurrence of new outbreaks. Dr DeBuse notes that from 2021 to 2031, PRRS virus is ex- pected to cost over US$ 8.0 billion in the US pig industry alone. “I believe we’re overlooking the importance of really solving this issue,” he says. If he could challenge his colleagues, he would ask them, “What might be done differently to ensure we are not know- ingly contributing to potential dual infections in utero dur- ing the 20 weeks immediately post-outbreak? Can we decrease substantially the occurrence of dual infected neonatal pigs in this time period by taking new approaches?”
PHOTO: DR NEIL DEBUSE
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
